Summary
PTEN is a novel tumour-suppressor gene located on chromosomal band 10q23.3. This region displays frequent loss of heterozygosity (LOH) in a variety of human neoplasms including breast carcinomas. The detection of PTEN mutations in Cowden disease and in breast carcinoma cell lines suggests that PTEN may be involved in mammary carcinogenesis. We here report a mutational analysis of tumour specimens from 103 primary breast carcinomas and constitutive DNA from 25 breast cancer families. The entire coding region of PTEN was screened by single-strand conformation polymorphism (SSCP) analysis and direct sequencing using intron-based primers. No germline mutations could be identified in the breast cancer families and only one sporadic carcinoma carried a PTEN mutation at one allele. In addition, all sporadic tumours were analysed for homozygous deletions by differential polymerase chain reaction (PCR) and for allelic loss using the microsatellite markers D10S215, D10S564 and D10S573. No homozygous deletions were detected and only 10 out of 94 informative tumours showed allelic loss in the PTENregion. These results suggest that PTEN does not play a major role in breast cancer formation.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bender, B., Wiestler, O. D. & Von Deimling, A. (1994). A device for processing large acrylamide gels. Biotechniques 16: 204–206.
Bloom, H. J. & Richardson, W. W. (1957). Histological grading and prognosis in breast cancer. A study of 1049 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359–377.
Bocker, T., Diermann, J., Friedl, W., Gebert, J., Holinski-Feder, E., Karner-Hanusch, J., von Knebel-Doeberitz, M., Koelble, K., Moeslein, G., Schackert, H. K., Wirtz, H. C., Fishel, R. & Ruschoff, J. (1997). Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res 57: 4739–4743.
Bostroem, J., Cobbers, JMJL, Wolter, M., Tabatabai, G., Weber, R. G., Lichter, P., Collins, V. P. & Reifenberger, G. (1998). Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome 10q. Cancer Res 58: 29–33.
Chen, J., Lindblom, P. & Lindblom, A. (1998). A study of the PTEN/MMAC1 gene in 136 breast cancer families. Hum Genet 102: 124–125.
Dahia, L. M., FitzGerald, M. G., Zhang, X., Marsh, D. J., Zheng, Z., Pietsch, T., von Deimling, A., Haluska, F. G., Haber, D. A. & Eng, C. (1998). A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene 16: 2403–2406.
Duerr, E. M., Rollbrocker, B., Hayashi, Y., Peters, N., Meyer-Putlitz, B., Louis, D. N., Schramm, J., Wiestler, O. D., Parsons, R., Eng, C. & von Deimling, A. (1998). PTEN mutations in gliomas and glioneuronal tumors. Oncogene 15: 2254–2259.
Fearon, E. R. (1997). Human cancer syndromes: clues to the origin and nature of cancer. Science 278: 1043–1050.
Guldberg, P., thor Straten, P., Birck, A., Ahrenkiel, V., Kirkin, A. F. & Zeuthen, J. (1997). Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57: 3660–3663.
Hayashi, Y., Ueki, K., Waha, A., Wiestler, O. D., Louis, D. N. & von Deimling, A. (1997). Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 7: 871–875.
Kerangueven, F., Eisinger, F., Noguchi, T., Allione, F., Wargniez, V., Eng, C., Padberg, G., Theillet, C., Jacquemier, J., Longy, M., Sobol, H. & Birnbaum, D. (1997). Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions. Oncogene 14: 339–347.
Kong, D., Suzuki, A., Zou, T. T., Sakurada, A., Kemp, L. W., Wakatsuki, S., Yokoyama, T., Yamakawa, H., Furukawa, T., Sato, M., Ohuchi, N., Sato, S., Yin, J., Wang, S., Abraham, J. M., Souza, R. F., Smolinski, K. N., Meltzer, S. J. & Horii, A. (1997). PTEN1 is frequently mutated in primary endometrial carcinomas (letter). Nat Genet 17: 143–144.
Lancaster, J. M., Wooster, R., Mangion, J., Phelan, C. M., Cochran, C., Gumbs, C., Seal, S., Barfoot, R., Collins, N., Bignell, G., Patel, S., Hamoudi, R., Larsson, C., Wiseman, R. W., Berchuck, A., Iglehart, J. D., Marks, J. R., Ashworth, A., Stratton, M. R. & Futreal, P. A. (1996). BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13: 238–240.
Li, D. M. & Sun, H. (1997). TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57: 2124–2129.
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H. & Parsons, R. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer (see comments). Science 275: 1943–1947.
Liaw, D., Marsh, D. J., Li, J., Dahia, P. L., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacocke, M., Eng, C. & Parsons, R. (1997). Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16: 64–67.
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., Bell, R., Rosenthal, J., Hussey, C., Tran, T., McClure, M., Frye, C., Hattler, T., Phelps, R., Haugen-Strano, A., Katcher, H., Yakumo, K., Gholami, Z., Shaffer, D., Stone, S., Bayer, S., Wray, C., Bogden, R., Dayananth, P., Ward, J., Tonin, P., Narod, S., Bristow, P. K., Norris, F. H., Helvering, L., Morrison, P., Rosteck, P., Lai, M., Barrett, C., Lewis, C., Neuhausen, S., Cannon-Albright, L., Goldgar, D., Wiseman, R., Kamb, A. & Skolnick, M. H. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71.
Miki, Y., Katagiri, T., Kasumi, F., Yoshimoto, T. & Nakamura, Y. (1996). Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 13: 245–247.
Nelen, M. R., van Staveren, W. C., Peeters, E. A., Hassel, M. B., Gorlin, R. J., Hamm, H., Lindboe, C. F., Fryns, J. P., Sijmons, R. H., Woods, D. G., Mariman, E. C., Padberg, G. W. & Kremer, H. (1997). Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 6: 1383–1387.
Rasheed, B. K., Stenzel, T. T., McLendon, R. E., Parsons, R., Friedman, A. H., Friedman, H. S., Bigner, D. D. & Bigner, S. H. (1997). PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57: 4187–4190.
Remmele, W., Hildebrand, U., Hienz, H. A., Klein, P. J., Vierbuchen, M., Behnken, L. J., Heicke, B. & Scheidt, E. (1986). Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol 409: 127–147.
Rhei, E., Kang, L., Bogomolniy, F., Federici, M. G., Borgen, P. I. & Boyd, J. (1997). Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 57: 3657–3659.
Schmutzler, R. K., Bierhoff, E., Werkhausen, T., Fimmers, R., Speiser, P., Kubista, E., Krebs, D., Zeillinger, R., Wiestler, O. D. & Von Deimling, A. (1997). Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma. Int J Cancer 74: 322–325.
Singh, B., Ittmann, M. M. & Krolewski, J. J. (1998). Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Cancer 21: 166–171.
Sourvinos, G., Kiaris, H., Tsikkinis, A., Vassilaros, S. & Spandidos, D. A. (1997). Microsatellite instability and loss of heterozygosity in primary breast tumours. Tumour Biol 18: 157–166.
Spiessl, B., Beahrs, O. B. & Hermanek, P. (1990). UICC TNM Atlas. Illustrated Guide to the TNM/pTNM Classification of Malignant Tumors, Springer Verlag Berlin
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D. H. & Tavtigian, S. V. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356–362.
Tashiro, H., Blazes, M. S., Wu, R., Cho, K. R., Bose, S., Wang, S. I., Li, J., Parsons, R. & Ellenson, L. H. (1997). Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935–3940.
Tsou, H. C., Teng, D. H., Ping, X. L., Brancolini, V., Davis, T., Hu, R., Xie, X. X., Gruener, A. C., Schrager, C. A., Christiano, A. M., Eng, C., Steck, P., Ott, J., Tavtigian, S. V. & Peacocke, M. (1997). The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases (in process citation). Am J Hum Genet 61: 1036–1043.
Ueda, K., Nishijima, M., Inui, H., Watatani, M., Yayoi, E., Okamura, J., Yasutomi, M., Nakamura, Y. & Miyoshi, Y. (1998). Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers. Jpn J Cancer Res 89: 17–21.
von Deimling, A., Bender, B., Louis, D. N. & Wiestler, O. D. (1993). A rapid and non-radioactive PCR based assay for the detection of allelic loss in human gliomas. Neuropathol Appl Neurobiol 19: 524–529.
Wang, S. I., Puc, J., Li, J., Bruce, J. N., Cairns, P., Sidransky, D. & Parsons, R. (1997). Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57: 4183–4186.
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C. & Micklem, G. (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature, (1996). 379: 749, Nature 378: 789–792
World Health Organization (1981). Histological Typing of Breast Tumours. 2nd International Classification of Tumors, World Health Organization Geneva
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Freihoff, D., Kempe, A., Beste, B. et al. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer 79, 754–758 (1999). https://doi.org/10.1038/sj.bjc.6690121
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690121
Keywords
This article is cited by
-
Breast cancer in the era of integrating “Omics” approaches
Oncogenesis (2022)
-
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
BMC Medicine (2012)
-
PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling
Oncogene (2012)
-
Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line
BMC Cancer (2011)
-
Targeting the phosphoinositide 3-kinase pathway in cancer
Nature Reviews Drug Discovery (2009)
